Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Launches Generic Drugs Canada

Hikma Expands In Canada With Four New Injectables

All Four Sterile Injectables Represent First Or Second Generic Versions In Canadian Market

  • News

Executive Summary

Hikma has bolstered its generic sterile injectables business in Canada with four new launches.

You may also be interested in...



Hikma Marks Milestone With US Injectables Launches

Hikma has passed a milestone with its US injectables portfolio after the latest trio of launches.

Juno Looks To Shore Up Canada Supply Chains With Omega Deal

Quickfire M&A has been unveiled in Canada, with Juno Pharmaceuticals taking control of the former Nichi-Iko affiliate Omega Laboratories.

Hikma Manages To Stay Flat In 2022 Despite Generics Pressures

As expected, Hikma’s generics business saw a significant slide in 2022 – but contributions from its successful injectables and brands divisions helped to stop an overall sales decline for the firm.

Table

View full table

Topics

Related Companies

Tags:
Launches Generic Drugs Canada
Latest Headlines

US FDA's Cavazzoni Criticizes Plant Shutdown That Triggered Serious Cisplatin Shortage

‘There Is Always Room For Improvement’: Celltrion Reflects On A Decade Of European Biosimilars

Fresenius Kabi Gets Ready To Launch Europe’s First Tocilizumab Rival

BioFactura Completes Phase I For Late-To-Market Stelara Biosimilar

See All
UsernamePublicRestriction

Register

GB152580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By